New! Sign up for our free email newsletter.
Science News
from research organizations

A more safe and efficient means for drug manufacturing

Date:
June 15, 2017
Source:
American Association for the Advancement of Science
Summary:
Scientists have developed a system that uses continuous flow technology, instead of a batch-by-batch approach, to produce pharmaceutical compounds, and they used it to manufacture a chemotherapy drug that's currently under evaluation in clinical trials.
Share:
FULL STORY

Scientists have developed a system that uses continuous flow technology, instead of a batch-by-batch approach, to produce pharmaceutical compounds, and they used it to manufacture a chemotherapy drug that's currently under evaluation in clinical trials.

Most pharmaceutical compounds are made in massive batches, yet small-volume continuous (SVC) manufacturing systems -- currently used to produce numerous commodity chemicals -- offer a number of advantages, such as improved safety and yield. As well, these systems can be used to conveniently produce pharmaceutical ingredients on site, when needed.

Yet, while a number of SVC manufacturing systems have successfully produced pharmaceutical compounds in laboratories, few adhere to "current good manufacturing practices," such that they are commercially scalable. Here, Kevin P. Cole and colleagues developed a SVC manufacturing system that does adhere to such standards.

The system allows for concurrent mixing of ingredients, and is equipped with fully automated filters that required no manual work, eliminating the risk of exposing operators to toxins. In this approach, a number of different techniques are used to separate layers of ingredients and effectively clean compartments after each use.

The team demonstrated the effectiveness of their system by producing the chemotherapy agent prexasertib, currently being assessed in a phase two trial as a chemotherapy agent, in aqueous form. The system yielded 24 kilograms of the compound over the course of three days, the authors report.


Story Source:

Materials provided by American Association for the Advancement of Science. Note: Content may be edited for style and length.


Journal Reference:

  1. Kevin P. Cole et al. Kilogram-scale prexasertib monolactate monohydrate synthesis under continuous-flow CGMP conditions. Science, 2017 DOI: 10.1126/science.aan0745

Cite This Page:

American Association for the Advancement of Science. "A more safe and efficient means for drug manufacturing." ScienceDaily. ScienceDaily, 15 June 2017. <www.sciencedaily.com/releases/2017/06/170615142751.htm>.
American Association for the Advancement of Science. (2017, June 15). A more safe and efficient means for drug manufacturing. ScienceDaily. Retrieved November 22, 2024 from www.sciencedaily.com/releases/2017/06/170615142751.htm
American Association for the Advancement of Science. "A more safe and efficient means for drug manufacturing." ScienceDaily. www.sciencedaily.com/releases/2017/06/170615142751.htm (accessed November 22, 2024).

Explore More

from ScienceDaily

RELATED STORIES